Angelini Pharma (Italy)

Recent papers from Angelini Pharma (Italy)

1. Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS studyEpilepsia · 2026
2. From inequity to action: Co-producing equitable access to specialist epilepsy care for adults − findings and approach from the PROPEL project (UK)Epilepsy & Behavior · 2026
3. Socioeconomic disparities and regional variation in access to newer anti-seizure medications: a nationwide Swedish cohort studyEpilepsy & Behavior · 2026
4. Digitally supported physical cancer rehabilitation during and after systemic treatment in South Baltic countries: Protocol for the AMBeR eRehab feasibility studyAdvances in Clinical and Experimental Medicine · 2026
5. Effectiveness of a two-year nature-based intervention in rising place attachment and connection with natureJournal of Adventure Education & Outdoor Learning · 2026
6. Beyond conventional: controlled-release fertilizers maintain yield, quality, and soil health with reduced environmental footprintScientific Reports · 2026
7. Effect of Concomitant Medications on Adverse Event Frequency, Severity, and Time to Resolution in a Cenobamate Open‐Label TrialEuropean Journal of Neurology · 2026
8. Exploring how patients, caregivers and clinicians experience pain across therapeutic areas in Italy: a multi-centre narrative medicine projectBMJ Open · 2026
9. AI-driven European Retrospective Database Study to predict disease onset in patients with epilepsy and depressionBMJ Neurology Open · 2026
10. Cenobamate: An Appraisal Five Years OnNeurology and Therapy · 2026
11. Cutting Pharma's Carbon Footprint: Reduced Emissions through Solvent Reuse2026
12. UXO-NM Framework: Nomadic Monadic Objects for Single-Life Situated Autonomous Acts2026
13. UXO-NM Framework: Nomadic Monadic Objects for Single-Life Situated Autonomous Acts2026
14. Perspectives on the burden of drug‐resistant epilepsy and treatment priorities: Findings from a multistakeholder surveyEpilepsia Open · 2026
15. Women with epilepsy: Evidence‐based counseling across the lifespanEpilepsia · 2026
16. Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatmentEpilepsy & Behavior · 2026
17. Effectiveness and Safety of the Combination of Paracetamol 1000 mg and Ibuprofen 300 mg Versus Ibuprofen 600 mg in Monotherapy in Acute Low Back Pain: Results from a Phase IV Randomized StudyJournal of Clinical Medicine · 2026
18. Combining Hyaluronic Acid and Amino Acids for Improved Healing of Post-Extraction Tooth Socket in Type 2 Diabetes Mellitus Subjects: A Randomized Clinical TrialDentistry Journal · 2026
19. Healthcare resource utilization in adults with focal onset seizures before and after initiating cenobamate: A US database analysisEpilepsy Research · 2026
20. Management of schizophrenia patients in acute setting – a multinational survey of prescription patterns in five European countriesInternational Journal of Psychiatry in Clinical Practice · 2025